% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. Message Board

  • df2830 df2830 May 7, 2014 4:25 PM Flag

    Are there slides? Anybody listening?

    Can't get any visuals

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • All Longs need to listen to the presentation which just ended but will be available later in Archive. Achillion would also entertain the idea for a 4 weeks treatment duration when scientific Data are available. Merck, yesterday has also initiate a POC trial using Gilead Sofosbuvir as base line fro a Nuc addition. Patience is a MUST here!

    • From the 10K just filed...will re-evaluate tomorrow

      In September 2013, the FDA requested, among other things, additional analysis to more fully characterize sovaprevir pharmacokinetics and the intrinsic and extrinsic factors that may lead to higher than anticipated exposures of sovaprevir or other potential toxicities in addition to the observed liver enzyme elevations. The FDA has approved our plan of analysis and additional clinical, non-clinical and pharmacokinetic data that we intend to submit shortly. We anticipate comment from the FDA during the second quarter of 2014.

7.93-0.09(-1.12%)May 5 4:00 PMEDT